Pfizer-BioNTech

Pfizer-high-revenues
Pfizer sees big reversal after reporting record high revenues, earnings in 2022
Pfizer sees big reversal after reporting record high revenues, earnings in 2022
US-to-approve-2nd-vaccine-booster-amid-mixed-pandemic-scenario
US to approve 2nd vaccine booster amid mixed pandemic scenario
US to approve 2nd vaccine booster amid mixed pandemic scenario
Pfizer-vaccine
Pfizer 2022 guidance comes shy of expectations despite strong growth projection
Pfizer 2022 guidance comes shy of expectations despite strong growth projection
Covid19-vaccination-immunity-virology
Study explores ways to get super immunity against Covid-19
Study explores ways to get super immunity against Covid-19
Pfizer-BioNTech
Pfizer, BioNTech start clinical trial of Omicron-specific Covid-19 vaccine
Pfizer, BioNTech start clinical trial of Omicron-specific Covid-19 vaccine
heart-inflammation-risk
Pfizer, CornoaVac vax linked to heart inflammation risk in adolescents
Pfizer, CornoaVac vax linked to heart inflammation risk in adolescents
Pfizer-anti-covid-drug
Hyderabad's Biophore to manufacture ingredients of Pfizer's Covid drug
Hyderabad's Biophore to manufacture ingredients of Pfizer's Covid drug
Pfizer-CEO
Pfizer CEO says this may be last Covid wave with restrictions
Pfizer CEO says this may be last Covid wave with restrictions
Pfizer
CDC advisers recommend Pfizer, Moderna vaccines over Johnson & Johnson
CDC advisers recommend Pfizer, Moderna vaccines over Johnson & Johnson
Pfizer
Third Pfizer vax dose more effective in reducing severe Covid illness: Lancet
Third Pfizer vax dose more effective in reducing severe Covid illness: Lancet
Advertisement